Alimera Announces Approval and Pricing Granted for ILUVIEN® for Uveitis in Italy
08 juil. 2022 08h00 HE
|
Alimera Sciences, Inc.
ATLANTA, July 08, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners...
Phase III Clinical Study IND Accepted in China for Alimera’s Fluocinolone Acetonide Intravitreal Implant
08 juin 2022 08h03 HE
|
Alimera Sciences, Inc.
ATLANTA, June 08, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners...
Alimera Sciences to Present at the LD Micro Invitational XII Conference
02 juin 2022 08h00 HE
|
Alimera Sciences, Inc.
ATLANTA, June 02, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners...
Phase 4 PALADIN Study Confirms Positive Predictive Value of Corticosteroid Course Prior to ILUVIEN® Use for IOP Outcomes
12 mai 2022 08h03 HE
|
Alimera Sciences, Inc.
ATLANTA, May 12, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners...
Alimera Sciences Reports First Quarter 2022 Results
09 mai 2022 08h00 HE
|
Alimera Sciences, Inc.
Consolidated Net Revenue of $11.9 Million Up 6% vs. First Quarter of 2021U.S. Net Revenue Increased 23% vs. First Quarter of 2021U.S. End User Demand Up 25% vs. First Quarter of 2021 ATLANTA, May ...
Alimera Sciences to Report First Quarter 2022 Financial Results on Monday, May 9, 2022, and Provide Corporate Update
06 mai 2022 08h00 HE
|
Alimera Sciences, Inc.
ATLANTA, May 06, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners...
Recent Alimera Data Featured in Scientific Programming at Upcoming Annual Congress
28 avr. 2022 08h30 HE
|
Alimera Sciences, Inc.
ATLANTA, April 28, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and...
Alimera Exhibits Continued Growth and Expansion With New Branding and Office Relocation
06 avr. 2022 08h00 HE
|
Alimera Sciences, Inc.
ATLANTA, April 06, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners...
Alimera Sciences to Present at the Q1 Investor Summit Conference
02 mars 2022 08h00 HE
|
Alimera Sciences, Inc.
ATLANTA, March 02, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners...
Alimera Sciences Reports Fourth Quarter and FY 2021 Results
24 févr. 2022 08h00 HE
|
Alimera Sciences, Inc.
Fourth Quarter Highlights: Consolidated Net Revenue of $14 Million Up 15% vs. Third Quarter of 2021; Up 1% vs. Fourth Quarter of 2020 Full Year 2021 Highlights: Consolidated Net Revenue of $59...